Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Unaudited Condensed Consolidated Statements of Cash Flows
Loss from continuing operations	$ (11,396)	$ (6,152)
Loss from disposal group	(6,967)	(2,683)
Net loss	(18,363)	(8,835)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of pharmaceutical assets and liabilities	565	0
Stock-based compensation - services	7	752
Stock issued from Equity Incentive Plan	0	(19)
Gain from extinguishment of debt	(40)	(735)
Change in fair value of contingent stock consideration	(513)	(947)
Change in fair value of convertible promissory notes	718	(1,111)
Impairment of intangibles	4,622	0
Depreciation and amortization	1,390	1,741
Amortization of right of use asset	71	63
Bad debt expense	0	6
Recovery of bad debt expense	(35)	(221)
Inventory reserve for obsolescence	108	176
Fair value of vested stock options and restricted stock	1,405	2,527
Changes in operating assets and liabilities:
Accounts receivable	(68)	10
Inventory	(127)	(529)
Prepaid expenses and other current assets	(61)	952
Other assets	(104)	(25)
Accounts payable	(1,178)	107
Accrued expenses	(2,012)	3,302
Operating lease payable	(79)	(68)
Contract liabilities	95	(598)
Assets and liabilities held for sale	5,112	795
Cash (used in) operating activities	(8,487)	(2,657)
Cash flows from investing activities:
Proceeds from the sale of certain pharmaceutical assets and liabilities	13,891	0
Long term assets held for sale	0	(99)
Purchase of note receivable	0	(200)
Collection of note receivable	0	200
Cash provided by (used in) investing activities	13,891	(99)
Cash flows from financing activities:
Proceeds from notes payable	252	1,000
Proceeds from notes payable - disposal group	4,150	0
Repayment of notes payable	(3,129)	0
Proceeds from related party payable	190	400
Repayment of related party payable	(2,243)	0
Proceeds from loans payable	38	0
Repayment of loans payable	(235)	(205)
Cash provided by (used in) financing activities	(977)	1,195
Net increase (decrease) in cash and cash equivalents	4,427	(1,561)
Cash and cash equivalents, beginning of year	16	1,725
Cash and cash equivalents, end of period	4,443	164
Cash paid for interest and income taxes:
Interest	585	102
Income taxes	0	0
Non-cash investing and financing activities:
Cancellation of indebtedness to Buyer of assets sold	(4,150)	0
Receipt of note payable consideration for assets sold	(2,000)	0
Common stock issued for conversion of promissory notes and accrued interest	666	2,881
Reclassification of accrued expense to related party payable	$ 42	$ 0